| scholarly article | Q13442814 |
| P50 | author | Ian F. Parney | Q47328401 |
| Rachael A Vaubel | Q89238682 | ||
| P2093 | author name string | Paul A Decker | |
| Jann N Sarkaria | |||
| James Watters | |||
| Karen E Parrish | |||
| William F Elmquist | |||
| Nathalie Y R Agar | |||
| Jeanette E Eckel-Passow | |||
| Shulan Tian | |||
| Fang Jin | |||
| David Calligaris | |||
| Aaron J Johnson | |||
| Panos Z Anastasiadis | |||
| Gaspar J Kitange | |||
| Ann C Mladek | |||
| Minjee Kim | |||
| Daniel J Ma | |||
| Ryan W Feathers | |||
| Shuangling Zhang | |||
| Laurent Debussche | |||
| Isabelle Meaux | |||
| Cedric Barriere | |||
| P2860 | cites work | Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX | Q24294074 |
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| VEGF Manipulation in Glioblastoma | Q26782692 | ||
| D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms | Q27663612 | ||
| Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme | Q28477660 | ||
| Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment | Q28548249 | ||
| Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging | Q29543337 | ||
| Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. | Q30596682 | ||
| High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. | Q30972928 | ||
| Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging | Q31133294 | ||
| Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases | Q33942964 | ||
| Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts | Q33953822 | ||
| MDM2, MDMX and p53 in oncogenesis and cancer therapy | Q34166049 | ||
| The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain | Q34458602 | ||
| The blood-brain barrier and cancer: transporters, treatment, and Trojan horses | Q34577796 | ||
| SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression | Q34584722 | ||
| Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. | Q34627868 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging | Q35007589 | ||
| Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. | Q35164218 | ||
| The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma | Q35463482 | ||
| Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses | Q35561280 | ||
| Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. | Q35799917 | ||
| T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents | Q35827906 | ||
| p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells | Q36048184 | ||
| Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease | Q36068294 | ||
| Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma | Q36107368 | ||
| Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model | Q36186193 | ||
| Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. | Q36484434 | ||
| SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. | Q36642763 | ||
| Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas | Q36828178 | ||
| Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab | Q36862845 | ||
| Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells | Q36946655 | ||
| microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. | Q36962411 | ||
| Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts | Q37027202 | ||
| Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain | Q37308322 | ||
| WWP2 is an E3 ubiquitin ligase for PTEN. | Q37588182 | ||
| Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier | Q38351134 | ||
| A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation | Q38830917 | ||
| Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models. | Q38850518 | ||
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer | Q38858580 | ||
| Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration | Q40559136 | ||
| Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis | Q41140259 | ||
| ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells | Q42515424 | ||
| Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting | Q43518666 | ||
| Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain | Q48183019 | ||
| Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent | Q48243402 | ||
| Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. | Q51978147 | ||
| CNS Metastases in Patients With Non-Small-Cell Lung Cancer and ALK Gene Rearrangement. | Q52145639 | ||
| Integrated platform for brain imaging and drug delivery across the blood-brain barrier | Q82478011 | ||
| P433 | issue | 9 | |
| P921 | main subject | blood–brain barrier | Q221694 |
| glioblastoma | Q282142 | ||
| P304 | page(s) | 1893-1901 | |
| P577 | publication date | 2018-07-03 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier | |
| P478 | volume | 17 |
| Q90752502 | Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy |
| Q91999689 | Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma |
| Q59329795 | Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma |
| Q99631176 | Systems biology approaches to measure and model phenotypic heterogeneity in cancer |
Search more.